Most clean tech businesses will spend three to seven years burning capital before generating a single pound of revenue, whether they are building a production plant or scaling a patented process.

This extended development phase is where most run out of cash before the science gets a chance to prove itself. How a company manages its money during this period matters more than how good the research is. Standard start-up playbooks assume you can reach revenue in 18 months with a laptop and a credit card. Hardware clean tech cannot do that.

Prototyping costs six figures and regulatory approval takes years. Production equipment is often designed from scratch, and the capital requirements are closer to biotech than SaaS. The funding ecosystem has not caught up.

Why standard funding models fall short

Venture capital works well for software. A seed round covers 18 months of product development. By the time traction proves the model, the next round is already in conversation.

Hardware clean tech breaks this pattern. Development timelines stretch beyond a single funding cycle, because building and testing a prototype recycling process or a synthetic fuel production line cannot be compressed into 18 months. Capital requirements compound the problem: lab equipment, raw materials, safety testing, and facility costs dwarf anything a typical software start-up faces. Revenue sits years away.

A business developing a novel materials recovery process may need industry certification, environmental permits, and pilot plant data before a single customer will sign a contract.

Software-based clean tech faces a different version of the same problem. A platform selling into construction, waste management, or energy may have a working product, but these are conservative industries with long procurement cycles. Revenue grows slowly even after the product is ready.

The cash flow forecast shows months or years of spending with no revenue to offset it.

R&D tax credits as a cash flow line

For loss-making clean tech businesses, R&D tax relief should sit in every quarterly forecast as a predictable source of cash, not a year-end surprise.

Under Enhanced R&D Intensive Support (ERIS), loss-making SMEs where qualifying R&D expenditure accounts for 30% or more of total expenditure can access an effective benefit of up to 27% of qualifying spend. A pre-revenue clean tech company spending £400,000 on qualifying R&D could receive a cash payment of up to £108,000.

Businesses that do not meet the ERIS intensity threshold, or which have moved into profitability, may instead claim under the merged R&D Expenditure Credit (RDEC-style) scheme. The effective benefit is lower, but for many scaling clean tech businesses it still represents a meaningful source of cash flow support.

Cash arrives after the accounting period ends and the claim is processed by HMRC, so timing the expected payment date into the forecast matters. For companies with a March year-end, payment typically arrives between September and December of the same year. Treating R&D credits as “sometime next year” rather than modelling the likely payment date creates unnecessary cash flow pressure.

That said, R&D tax relief should support a cash flow forecast, not determine whether the business survives. HMRC expects companies to remain financially viable without depending on the repayment arriving. If payroll or supplier commitments can only be met once the R&D claim is paid, the business is already exposed to timing and compliance risk.

Since April 2024, grant-funded R&D qualifies for the same relief as any other qualifying expenditure (we covered the rule change in detail in our R&D tax relief article). Many businesses have not yet factored this into their forecasts.

Grant drawdown timing

Innovate UK grants are milestone-based. Money arrives after you complete a project stage, submit evidence, and pass review. It does not arrive when you need to pay the bill.

A typical pattern: a clean tech business commits to a six-month work package costing £150,000. The grant covers 70% of eligible costs. But the grant payment lands four to eight weeks after the milestone report is approved. For a company with limited reserves, that gap can force difficult decisions about which suppliers to pay and which staff to retain.

Two practices reduce the risk:

  • Align major expenditure commitments with milestone schedules wherever possible. If a large equipment purchase falls between milestones, the cash requirement spikes at the worst time.
  • Maintain a rolling schedule of milestone dates, expected claim values, and realistic payment timescales. Optimistic assumptions about when Innovate UK will release funds have caught out more than one early-stage company.

Innovation Loans and repayable finance

Innovate UK offers Innovation Loans of £100,000 to £2 million. These are repayable with no equity dilution. For clean tech businesses that want to avoid further share issuance, they fill a gap between grant funding and equity rounds.

Most applicants fail at the commercial viability stage, because Innovate UK needs confidence the loan will be repaid. A pre-revenue company with no clear path to sales within the loan term will struggle. Businesses that have completed their R&D phase and need capital to move from pilot to production, with letters of intent or offtake agreements in hand, fit the criteria best.

Loan repayments add to the cash flow burden at a later stage. Modelling the repayment schedule against projected revenue is not optional.

Stacking funding sources without losing relief

Most clean tech businesses use a combination of equity (SEIS/EIS), grants, R&D tax credits, and potentially Innovation Loans. The interactions between these funding sources are where money gets left on the table or compliance problems are created.

For accounting periods beginning before 1 April 2024, grants did not prevent an R&D claim, but they often pushed the funded expenditure into the less favourable RDEC scheme rather than the SME scheme.

For accounting periods beginning on or after 1 April 2024, the merged RDEC-style scheme and ERIS now sit alongside each other, with ERIS available only to qualifying loss-making R&D intensive SMEs. This makes the modelling cleaner, but not simpler. You still need to understand which scheme applies, what rate of relief is available, and how the timing of the cash receipt fits into the forecast.

Grants can still affect other areas. Where grant funding contributes towards capital equipment, it may reduce the capital allowances available on that asset.

A business receiving a £300,000 grant towards a £500,000 piece of production equipment can only claim capital allowances on the net £200,000. Getting the accounting wrong means either overstating the allowance claim, which creates a compliance risk, or missing the R&D credit on the revenue portion of the project, which leaves cash on the table.

SEIS and EIS equity funding has its own constraints. The EIS gross assets limit doubled to £30 million from April 2026, giving clean tech businesses more headroom, but maintaining qualifying status still requires careful monitoring of the employee count, trading activity rules, and the new thresholds. A clean tech business that inadvertently breaches an EIS condition can trigger clawback of tax relief from its investors. That can trigger investor legal action to recover the relief.

What the forecast should include

Pre-revenue clean tech companies have no customer receipts to forecast. Income comes from a small number of large, irregular sources: equity rounds, grant payments, and R&D credit refunds.

Start with a 12 to 24 month rolling cash flow forecast. It should map every known funding inflow against committed and planned expenditure, with realistic timing assumptions for each.

Track R&D intensity as a percentage of total spend within the same model. Falling below the 30% threshold means losing access to ERIS, which for a loss-making company can reduce the effective R&D benefit from 27% to 16.2%.

Clean cost allocation from the start saves money at every subsequent stage. Separating R&D costs from operational costs in the accounting records determines whether R&D claims hold up and whether the company maintains ERIS eligibility. It also shapes the quality of information available to investors during due diligence.

Report to the board at every milestone, even if the board is two founders and an angel investor. If spending is running ahead of the plan and the next funding event is six months away, that conversation is better had now than in three months.

When to bring in an accountant

Get specialist advice in place before the first grant application. Waiting until the first cash flow crisis costs more to fix.

An accountant who understands clean tech funding can structure the chart of accounts to capture R&D costs correctly from day one. That same expertise extends to modelling R&D intensity across different spending scenarios and protecting ERIS eligibility. Where grant drawdowns, R&D claims, and capital allowances interact, getting advice before a claim is submitted avoids the cost of correcting it after HMRC queries arrive.

For pre-revenue businesses, the accountant’s role goes beyond compliance. It covers the financial model behind the next funding round and the records that make both grant applications and R&D claims defensible.

Bringing in a specialist after two years of unstructured accounting means paying to reconstruct records that should have existed from the start. It also means the first R&D claim is harder to evidence and more likely to attract questions.

How Wilson Partners can help

Wilson Partners works with clean tech and circular economy businesses from pre-revenue through to production and scale. If your cash flow model does not yet account for the timing of R&D credits, grant drawdowns, and capital allowances, our team can review it and identify where money is being left on the table. Request a cash flow review.

Frequently asked questions

How do I forecast R&D tax credit payments for cash flow purposes?

R&D tax credits are paid after the accounting period ends and the corporation tax return, including the R&D claim, has been submitted and processed by HMRC. In practice, this means there can be a significant delay between spending the money and receiving the cash benefit.

For example, if a company has a 31 December 2025 year-end, expenditure incurred in January 2025 may not generate a cash repayment until around June 2026. That creates a gap of roughly 18 months between the earliest qualifying spend and receipt of the credit.

Build this timing lag into your rolling cash flow forecast using realistic filing and HMRC processing assumptions rather than treating the repayment as near-term working capital.

Can I claim R&D tax relief on work funded by an Innovate UK grant?

Yes. From April 2024, the subsidised expenditure rules were removed. Grant-funded R&D qualifies for relief under both the merged scheme and ERIS on the same basis as self-funded expenditure.

What happens if my R&D spending drops below 30% of total expenditure?

You lose access to ERIS, which provides the highest effective relief rate for loss-making companies. A one-year grace period applies: if you met the threshold in the previous year and claimed ERIS, you can continue to claim ERIS for one further year even if your intensity drops below 30%. After that, you revert to the standard merged scheme.

Should I take an Innovation Loan or raise more equity?

It depends on your stage and revenue outlook. Innovation Loans preserve equity but require repayment, so they suit businesses close to revenue. Equity is better suited to pure R&D stage businesses where repayment capacity is uncertain. Your accountant should model both options against your cash flow forecast.

Sources:

Sign up to receive alerts

Read more articles by

See all articles
Call us on 0330 057 6265 for a no-obligation chat